Published in Drug Law Weekly, August 15th, 2006
The newly issued U.S. patent (U.S. Patent No. 7,078,196 or " '196 patent") broadly covers methods of making small interfering RNAs (siRNAs), the molecules that mediate RNAi, and includes 79 claims covering chemical modifications needed to introduce "drug-like" properties in RNAi therapeutics. The issued patent is exclusively licensed to Alnylam for RNAi therapeutics on a worldwide basis through an agreement with Garching Innovation...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.